Assessing prolactin concentrations within breast tumours may allow us to predict the response to current chemotherapeutic drugs; in addition, it supports the use of effective prolactin antagonists, since they may provide a better, more effective therapeutic intervention for some breast cancers. Here, PRL is linked to breast carcinoma.